[go: up one dir, main page]

WO2003023060A3 - Verfahren und kit zur diagnostik oder behandlungskontrolle von brustkrebs - Google Patents

Verfahren und kit zur diagnostik oder behandlungskontrolle von brustkrebs Download PDF

Info

Publication number
WO2003023060A3
WO2003023060A3 PCT/EP2002/009999 EP0209999W WO03023060A3 WO 2003023060 A3 WO2003023060 A3 WO 2003023060A3 EP 0209999 W EP0209999 W EP 0209999W WO 03023060 A3 WO03023060 A3 WO 03023060A3
Authority
WO
WIPO (PCT)
Prior art keywords
diagnosing
kit
treatment
controlling
breast cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/009999
Other languages
English (en)
French (fr)
Other versions
WO2003023060A2 (de
Inventor
Alf-Andreas Krehan
Pia Steffens
Bertha Gutierrez
Stefanie Waschuetza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alere Diagnostics GmbH
Original Assignee
Adnagen GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10143776A external-priority patent/DE10143776A1/de
Priority claimed from PCT/EP2002/005489 external-priority patent/WO2003023057A2/de
Application filed by Adnagen GmbH filed Critical Adnagen GmbH
Priority to US10/488,828 priority Critical patent/US20050014208A1/en
Priority to EP02774579A priority patent/EP1409746A2/de
Publication of WO2003023060A2 publication Critical patent/WO2003023060A2/de
Publication of WO2003023060A3 publication Critical patent/WO2003023060A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Die vorliegende Erfindung bezieht sich auf ein Verfahren und ein Kit zur Diagnostik oder Behandlungskontrolle von Brustkrebs bei einem Menschen. Dieses Verfahren basiert darauf, dass in einer Blutprobe des Menschen das Vorhandensein oder Fehlen von mindestens zwei verschiedenen mRNS erfasst wird, die für verschiedene der Tumormarkerproteine EGF-R, CEA, Stanniocalcin, CK20, MAGE-3, GA733.2, MUC1, Her-2/neu, Claudin-7 und/oder PDGF-β kodieren und daraus auf das Vorhandensein von Mammakarzinomzellen in der Blutprobe und damit auf mögliche Metastasierung geschlossen wird.
PCT/EP2002/009999 2001-09-06 2002-09-06 Verfahren und kit zur diagnostik oder behandlungskontrolle von brustkrebs Ceased WO2003023060A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/488,828 US20050014208A1 (en) 2001-09-06 2002-09-06 Method and kit for diagnosing or controlling the treatment of breast cancer
EP02774579A EP1409746A2 (de) 2001-09-06 2002-09-06 Verfahren und kit zur diagnostik oder behandlungskontrolle von brustkrebs

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10143776A DE10143776A1 (de) 2001-09-06 2001-09-06 Verfahren und Kit zur Diagnostik oder Behandlungskontrolle von Brustkrebs
DE10143776.5 2001-09-06
PCT/EP2002/005489 WO2003023057A2 (de) 2001-09-06 2002-05-17 Verfahren und diagnose-kit zur selektionierung und/oder zum qualitativen und/oder quantitativen nachweis von zellen
EPPCT/EP02/05489 2002-05-17

Publications (2)

Publication Number Publication Date
WO2003023060A2 WO2003023060A2 (de) 2003-03-20
WO2003023060A3 true WO2003023060A3 (de) 2004-01-29

Family

ID=26010082

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/009999 Ceased WO2003023060A2 (de) 2001-09-06 2002-09-06 Verfahren und kit zur diagnostik oder behandlungskontrolle von brustkrebs

Country Status (2)

Country Link
EP (1) EP1409746A2 (de)
WO (1) WO2003023060A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2253533T3 (es) 2001-09-06 2006-06-01 Adnagen Ag Procedimiento para la deteccion cualitativa y/o cuantitativa de celulas.
US20070134670A1 (en) * 2003-12-12 2007-06-14 Bayer Pharmaceuticals Corporation Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2006017635A2 (en) * 2004-08-11 2006-02-16 Albert Einstein College Of Medicine Of Yeshiva University Isolation, gene expression, and chemotherapeutic resistance of motile cancer cells
JP2006223194A (ja) * 2005-02-17 2006-08-31 Tosoh Corp スタニオカルシン１（ＳＴＣ１）ｍＲＮＡの測定方法
FR2899239A1 (fr) * 2006-03-31 2007-10-05 Biomerieux Sa Procede de detection du cancer
FR2892730A1 (fr) * 2005-10-28 2007-05-04 Biomerieux Sa Methode pour detecter la presence ou le risque de developper un cancer
WO2007048978A2 (fr) * 2005-10-28 2007-05-03 Biomerieux Sa Procede de detection du cancer
EP2088204A1 (de) * 2008-02-05 2009-08-12 Adnagen AG Verfahren und Kit zur Diagnose bzw. Kontrolle der Behandlung von Ovarialkarzinomen
GB201000688D0 (en) * 2010-01-15 2010-03-03 Diagenic Asa Product and method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007139A1 (en) * 1992-09-14 1994-03-31 Fodstad Oystein Improved method for detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations
DE19736691A1 (de) * 1997-08-22 1999-02-25 Michael Prof Dr Med Giesing Verfahren zur Charakterisierung und Identifizierung disseminierter und metastasierter Krebszellen
WO1999044064A1 (en) * 1998-02-27 1999-09-02 Cli Oncology, Inc. Method and compositions for differential detection of primary tumor cells and metastatic cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007139A1 (en) * 1992-09-14 1994-03-31 Fodstad Oystein Improved method for detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations
DE19736691A1 (de) * 1997-08-22 1999-02-25 Michael Prof Dr Med Giesing Verfahren zur Charakterisierung und Identifizierung disseminierter und metastasierter Krebszellen
WO1999044064A1 (en) * 1998-02-27 1999-09-02 Cli Oncology, Inc. Method and compositions for differential detection of primary tumor cells and metastatic cells

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BALZAR M ET AL: "The biology of the 17-1A antigen (Ep-CAM)", JOURNAL OF MOLECULAR MEDICINE, SPRINGER VERLAG, DE, vol. 77, no. 10, October 1999 (1999-10-01), pages 699 - 712, XP000925817, ISSN: 0946-2716 *
CHARPENTIER A H ET AL: "STC2 AND E2IG1, TWO NOVEL BREAST CANCER BIOMARKERS", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 42, no. 628, March 2001 (2001-03-01), pages 628, XP001119829, ISSN: 0197-016X *
CHRYSOGELOS S A ET AL: "EGF RECEPTOR EXPRESSION, REGULATION, AND FUNCTION IN BREAST CANCER", BREAST CANCER RESEARCH AND TREATMENT, NIJHOFF, BOSTON, US, vol. 29, no. 1, 1994, pages 29 - 40, XP001118068, ISSN: 0167-6806 *
COLTRERA MARC D ET AL: "Expression of Platelet-derived Growth Factor B-Chain and the Platelet-derived Growth Factor Receptor beta Subunit in Human Breast Tissue and Breast Carcinoma.", CANCER RESEARCH, vol. 55, no. 12, 1995, pages 2703 - 2708, XP001153992, ISSN: 0008-5472 *
FUJIWARA Y ET AL: "ASSESSMENT OF STANNIOCALCIN-1 MRNA AS A MOLECULAR MARKER FOR MICROMETASTASES OF VARIOUS HUMAN CANCERS", INTERNATIONAL JOURNAL OF ONCOLOGY, EDITORIAL ACADEMY OF THE INTERNATIONAL JOURNAL OF ONCOLOGY,, GR, vol. 16, April 2000 (2000-04-01), pages 799 - 804, XP002938551, ISSN: 1019-6439 *
GHOSSEIN R A ET AL: "Molecular detection of micrometastases and circulating tumor cells in solid tumors", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 5, no. 8, August 1999 (1999-08-01), pages 1950 - 1960, XP002225510, ISSN: 1078-0432 *
HARDINGHAM J E ET AL: "IMMUNOBEAD-PCR: A TECHNIQUE FOR THE DETECTION OF CIRCULATING TUMOR CELLS USING IMMUNOMAGNETIC BEADS AND THE POLYMERASE CHAIN REACTION", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 53, 1 August 1993 (1993-08-01), pages 3455 - 3458, XP000605489, ISSN: 0008-5472 *
MARTIN KATHERINE J ET AL: "High-sensitivity array analysis of gene expression for the early detection of disseminated breast tumor cells in peripheral blood", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 98, no. 5, 27 February 2001 (2001-02-27), pages 2646 - 2651, XP002188522, ISSN: 0027-8424 *
NACHT MARIANA ET AL: "Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, no. 21, 1 November 1999 (1999-11-01), pages 5464 - 5470, XP002166291, ISSN: 0008-5472 *
RACILA E ET AL: "Detection and charcterization of carcinoma cells in the blood", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 95, April 1998 (1998-04-01), pages 4589 - 4594, XP002132943, ISSN: 0027-8424 *
SMITH B ET AL: "DETECTION OF MELANOMA CELLS IN PERIPHERAL BLOOD BY MEANS OF REVERSE TRANSCRIPTASE AND POLYMERASE CHAIN REACTION", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 338, 16 November 1991 (1991-11-16), pages 1227 - 1229, XP002008751, ISSN: 0140-6736 *
ZHONG X Y ET AL: "EVALUATING GA733-2 MRNA AS A MARKER FOR THE DETECTION OF MICROMETASTATIC BREAST CANCER IN PERIPHERAL BLOOD AND BONE MARROW", ARCHIVES OF GYNECOLOGY AND OBSTETRICS, SPRINGER VERLAG, BERLIN, DE, vol. 263, no. 1/2, 1999, pages 2 - 6, XP000929386, ISSN: 0932-0067 *

Also Published As

Publication number Publication date
WO2003023060A2 (de) 2003-03-20
EP1409746A2 (de) 2004-04-21

Similar Documents

Publication Publication Date Title
EP2022800A3 (de) Zusammensetzungen zur Behandlung und Diagnose von Eierstockkrebs
NZ512247A (en) Compositions and methods for therapy and diagnosis of ovarian cancer
WO2002016413A3 (en) Cripto tumour polypeptide
WO2001008636A8 (en) Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
ATE485520T1 (de) Mittel und methoden für die diagnose, behandlung und vorbeugung von auf steroid hormone reagierende krebskrankheiten
NZ330887A (en) Monoclonals and polyclonals antibodies for the diagnosis of breast cancer
WO2005001092A3 (en) Compositions and methods for diagnosing and treating cancers
TR200001646T2 (tr) Bir salgılanmış meme kanseri proteini olan mamaglobin.
DE69717664D1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
WO2001079286A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2003023060A3 (de) Verfahren und kit zur diagnostik oder behandlungskontrolle von brustkrebs
EP1272636B8 (de) In brust- und blasenkrebs differentiell exprimiertes gen und durch dieses kodierte polypeptide
NO174719C (no) Fremgangsmåte for fremstilling av monoklonale antistoffer
Cheng et al. Markers of malignant prostate cancer cells: Golgi localization of α-mannosidase 1A at GM130-GRASP65 site and appearance of high mannose N-glycans on cell surface
WO2003023059A3 (de) Verfahren und kit zur diagnostik oder behandlungskontrolle von darmkrebs
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
ES2101695T3 (es) Haptoglobina relacionada con el cancer (hpr).
EP1696028A3 (de) Zusammensetzungen und Methoden zur Therapie und Diagnose von Brustkrebs
EP0839908A3 (de) ELF3, ein Mitglied der ETS-Familie
ATE475710T1 (de) Zusammensetzungen und verfahren für die therapie und diagnose von ovariumkrebs
WO2005042578A3 (en) Antibody fab fragment specific for breast cancer
DE60144204D1 (de) 84P2A9: Prostata- und hodenspezifisches Protein, das sehr stark bei Prostatakrebs vorkommt
BG102177A (en) Surgical method for organconservation treatment of cancer of the mammary gland
ATE359377T1 (de) Verfahren und kit zur diagnostik oder behandlungskontrolle von darmkrebs
WO2003042700A3 (en) Breast cancer associated polypeptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FR GB GR IE IT LU MC NL PT SE SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002774579

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002774579

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10488828

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP